Print this page    •   Back to Web version of article

Medical News
Setback for Gilead Hepatitis C Drug

February 21, 2012

Gilead Sciences Inc. on Friday announced that a majority of hepatitis C virus patients in one arm of a clinical trial relapsed after treatment with an experimental drug. Gilead obtained the drug, GS-7977, through its $11 billion purchase of Pharmasset last month. Gilead wants GS-7977 to serve as the anchor for what it hopes will be the first all-oral HCV treatment regimen. The relapses cited involved patients with HCV genotype 1 who previously had little or no response to an interferon-based regimen. The results suggest additional antiviral drugs may be needed, which Gilead said it will be exploring. GS-7977 has shown positive results with other HCV genotypes, including genotypes 2 and 3. Further trial results, including for treatment-naive HCV genotype 1 patients, will be released in the coming months.

Back to other news for February 2012

Excerpted from:
Wall Street Journal
02.17.2012; Peter Loftus




This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. You can find this article online by typing this address into your Web browser:
http://www.thebody.com/content/65877/setback-for-gilead-hepatitis-c-drug.html

General Disclaimer: TheBody.com is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through TheBody.com should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.